Extramammary Paget disease: Failure to respond to topical imiquimod 5%

On, Shelbi C. Jim; Izumi, Allan K.

doi:10.1016/j.jaad.2010.04.035

Cited by 14 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In non‐surgical candidates, some reports and small case series, however, have suggested that applying 5% imiquimod cream daily or two to three times a week for a minimum of 8–16 weeks may be beneficial with at times excellent results that may reach an 87.5% cure rate . Yet, therapeutic failure with disease progression has been reported in few cases . Some have also described imiquimod as neoadjuvant therapy before surgery, leading to tumor size reduction with subsequent easier surgical excision .…”

Section: Off‐label Uses Of Imiquimod In Cutaneous Disordersmentioning

confidence: 99%

Imiquimod in dermatology: an overview

2016

View full text Add to dashboard Cite

Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream. Topical imiquimod stimulates the innate and adaptive immune responses and induces cytokine production. This allows its use for the treatment of a wide variety of benign and malignant skin conditions due to its potential antiviral, antitumor, and immunoregulatory effects. Currently, topical imiquimod is US Food and Drug Administration (FDA)-approved for the treatment of anogenital warts, actinic keratosis, and superficial basal cell carcinomas. However, it has also shown a beneficial effect in the treatment of many other skin disorders. In this review, we describe existing evidence on the mechanism of action of topical imiquimod, its FDA-approved indications, off-label uses, and side effects.

show abstract

Section: Off‐label Uses Of Imiquimod In Cutaneous Disordersmentioning

confidence: 99%

Imiquimod in dermatology: an overview

2016

View full text Add to dashboard Cite

show abstract

“…Green et al . suggested that one of the factors resulting in failure may be the inability to confirm tumor invasion before treatment . The efficacy of imiquimod in invasive EMPD has not been reported.…”

Section: Discussionmentioning

confidence: 99%

Imiquimod 5% cream as a therapeutic option for extramammary Paget's disease

Sawada

Kato

Yamashita

et al. 2017

The Journal of Dermatology

View full text Add to dashboard Cite

A wide local excision is the standard treatment for extramammary Paget's disease (EMPD), though this treatment often leads to permanent anogenital mutilation and functional impairment. The purpose of our study is to evaluate the efficacy and safety of the topical application of imiquimod 5% cream for non-invasive EMPD. We examined nine patients with EMPD. Eight of the nine patients were treated with imiquimod 5% cream three times per week for 16 weeks; one case was treated for 6 weeks. The response rate was 100% including five complete remissions. Local irritation was observed in three patients, which was controlled by a provisional withdrawal of the treatment. These results suggest that imiquimod 5% cream may be considered an alternative therapeutic option for the treatment of non-invasive EMPD.

show abstract

“…With respect to the EMPD prognosis in general, it is limited by the multifocal nature of EMPD [8] . Topical treatment using imiquimod 5% has been reported in the past few years with varying results, occasionally yielding remissions in small tumors and in recurrent cases [3,4,13] . However, there is a need for larger controlled trials to accurately determine the efficacy, as well as the safety of the imiquimod 5% cream [3,4] .…”

Section: Discussionmentioning

confidence: 99%

Surgical treatment of Paget’s disease of the vulva using Mohs micrographic surgery, followed by vulvar reconstruction using the “lotus petal” suprafascial flap

Llueca¹,

Herráiz²,

Maazouzi³

et al. 2016

Adv Mod Oncol Res

View full text Add to dashboard Cite

Vulvar Paget's disease is an extramammary manifestation of Paget's disease, a cutaneous neoplasm that clinically appears as sharply defined erythematous plaques with irregular borders that usually affect apocrine gland-bearing skin. Extramammary Paget's disease (EMPD) of the vulva can remain undiagnosed for years and could be associated with multifocal neoplasms. The current gold standard for the treatment of vulvar EMPD is surgical excision and the Mohs micrographic surgery is the preferred technique used in evaluating the margins of the specimen. The reconstruction of the vulva using suprafascial flaps reduces hospitalization time and complications rate.

show abstract

Extramammary Paget disease: Failure to respond to topical imiquimod 5%

Cited by 14 publications

References 5 publications

Imiquimod in dermatology: an overview

Imiquimod in dermatology: an overview

Imiquimod 5% cream as a therapeutic option for extramammary Paget's disease

Surgical treatment of Paget’s disease of the vulva using Mohs micrographic surgery, followed by vulvar reconstruction using the “lotus petal” suprafascial flap

Contact Info

Product

Resources

About